ICD-116A22	SCHIZOTYPAL DISORDER Schizotypal disorder
ICD-10F21	Schizotypal disorder
DSM-5-TRF21	Schizotypal Personality Disorder

1. Definition and nosology

Schizotypal disorder (ICD-11: 6A22 Schizotypal Disorder; DSM-5-TR: F21 Schizotypal Personality Disorder) — a clinical condition characterized by persistent thought and perception disturbances, bizarre (eccentric) behavior, social deficits, and psychotic-like experiences, but not meeting the criteria for a full psychotic episode.

Important nosological issue: Different placement in ICD-11 and DSM-5-TR:

• ICD-11 — within schizophrenia spectrum disorders (psychotic category), 6A22;
• DSM-5-TR — in the personality disorders chapter (Cluster A) and, at the same time, in the schizophrenia spectrum disorders list — double-coded.

2. History

• Bleuler E. (1911) — latent schizophrenia — a condition closely related to schizophrenia but without a full psychotic episode.
• Rado S. (1953) — The term “schizotype” refers to a persistent personality expression of genetic predisposition to schizophrenia.
• Kety S.S. et al. (1968) — Danish adoptive studies — high schizotypal traits in biological relatives of schizophrenia; basis of “schizophrenia spectrum” concept.
• DSM-III (1980) — Schizotypal Personality Disorder among personality disorders.
• ICD-10 (1990) and ICD-11 (2019) — Schizotypal disorder in psychotic disorders chapter.
• DSM-5 (2013) — Double placement (personality disorders + schizophrenia spectrum) — conceptual bridge.

3. Epidemiology

• Lifetime prevalence: 0.6–4% — wide range (Pulay A.J. et al. Prim Care Companion J Clin Psychiatry 2009 US NESARC study n>34,000 — 3.9%).
• Sex: Relatively frequent in males; difference minimal in some studies.
• Onset: Adolescence and early adulthood period.
• Transition to schizophrenia: 10–25% (Schultze-Lutter F. et al. Schizophr Res 2014); higher when there is a family history and additional psychosis risk factors.
• Comorbidity: Mood disorders, anxiety, substance use, other personality disorders (paranoid, schizoid, borderline).

4. Aetiology and pathogenesis

4.1 Genetic factors

• Shared genetic burden with schizophrenia — Kety adoptive studies and modern genetic research (Cross-Disorder Group 2013) — risk of schizophrenia is increased in relatives of schizotypal patients.
• Polygenic risk architecture similar to schizophrenia, but lesser ‘load’; presence of some protective alleles.

4.2 Neurobiology

• Observed milder variants of structural changes in schizophrenia — volume reduction of temporal cortex, but preservation of frontal cortex (Hazlett E.A. et al. Schizophr Bull 2011 review).
• Dopaminergic dysregulation — lower than in schizophrenia; psychotic decompensation less likely.
• Cognitive deficits — as in schizophrenia, but milder.

4.3 Environmental factors

• Childhood trauma, social deprivation — risk factors.
• Cannabis use in adolescence increases the risk of psychotic decompensation.

5. Clinical features

5.1 Cognitive-perceptual symptoms

• Referential delusions (ideas of reference) — not at full delusional level; the patient may at times recognise these thoughts as unreal.
• Odd beliefs or magical thinking – telepathy, ‘sixth sense,’ superstitions inappropriate to age and culture.
• Unusual perceptual experiences – impersonal, transient illusions; full hallucination absent.
• Odd thinking and speech – vague, metaphorical, indirect, stereotyped.

5.2 Interpersonal symptoms

• Discomfort in close relationships; social isolation.
• Paranoid idea or suspiciousness.
• Inappropriate or restricted affect.
• Odd, eccentric, or peculiar behavior and appearance.
• Scarcity of close friends other than first-degree relatives.

5.3 Course

Typically begins in adolescence and runs a continuous course; some patients may have brief psychotic decompensation episodes (in the context of stress, cannabis) — at which point the diagnosis may be reassessed as ‘schizophrenia’ or ‘acute and transient psychotic disorder’.

6. Diagnosis

6.1 Unified diagnostic criteria (DSM-5-TR · ICD-11 consensus points)

A. Social and interpersonal deficits and cognitive-perceptual disturbances characterized by persistent pattern, onset in adulthood, at least the following symptoms five:

1. Relationship thoughts (excluding referential delusions);
2. Beliefs or magical thinking inconsistent with age and culture;
3. Unusual perceptual experiences (including illusions);
4. Odd thinking and speech (vague, indirect, metaphorical, stereotyped);
5. Suspiciousness and paranoid ideas;
6. Inappropriate or restricted affect;
7. Odd, eccentric, or peculiar behavior or appearance.
8. Scarcity of close friends or confidants other than first-degree relatives;
9. Extreme social anxiety not decreasing with familiarity (based on paranoid fear, not self-esteem).

B. Does not occur during the course of persistent schizophrenia, affective disorder with psychotic features, or autism spectrum disorder.

6.2 Source-specific clarifications

• ICD-11 (6A22): “Schizotypal Disorder” — in the chapter on psychotic disorders; as a persistent disorder, but not meeting criteria for schizophrenia.
• DSM-5-TR (F21): dual coding — Cluster A Personality Disorder and schizophrenia spectrum listing. Adult age requirement; in childhood and adolescence may be recorded as “premorbid features.”
• NICE: no specific clinical guidelines for schizotypal disorder; principles from CG78 (BPD) and CG178 (Psychosis) apply.

6.3 Diagnostic algorithm

1. Clinical interview + relative/friend information — enduring personality traits vs episodic psychosis.
2. Structured interview — SCID-5-PD (Personality Disorders), SIDP-IV.
3. Schizotypy scales — SPQ (Schizotypal Personality Questionnaire, Raine A.).
4. Separate assessment of psychotic symptoms — subclinical level of positive symptoms on PANSS.
5. Comorbidity screening (depression, anxiety, substance use, other personality disorders).
6. Medical and neurological examination, toxicological screening.
7. Assessment of transition risk to schizophrenia (ultra-high risk criteria — CAARMS, SIPS).

6.4 Differential diagnosis

7. Examination and assessment

7.1 Clinical scales

• SPQ (Schizotypal Personality Questionnaire, Raine A.) — 74 items, self-report; 9 subscales (based on DSM criteria).
• SCID-5-PD — structured personality disorder interview.
• CAARMS (Comprehensive Assessment of At Risk Mental States) — risk assessment for transition to schizophrenia.
• SIPS (Structured Interview for Prodromal Syndromes).
• PANSS, BPRS — subclinical level of psychotic symptoms.

7.2 Laboratory investigations

No specific routine indication. Standard psychiatric initial indicators (complete blood count, thyroid, liver, kidney, glucose); toxicological screening.

7.3 Instrumental investigations

Not routinely required; neuroimaging in clinical suspicion.

8. Treatment

8.1 General principles

1. Psychotherapy first line — supportive psychotherapy, CBT (especially for paranoid thinking and social anxiety), social skills training.
2. Pharmacotherapy is symptomatic, does not cure the “core” disorder:
   • Low-dose antipsychotic (risperidone 0.5–2 mg, olanzapine 2.5–10 mg, aripiprazole 2–10 mg) — for psychotic-like symptoms; intermittent, not continuous.
   • SSRI — for social anxiety and comorbid depression.
   • Benzodiazepine short-term — acute anxiety.
3. Early Intervention Services (EIP) — Preventive intervention in patients at risk of transition to schizophrenia (UHR — Ultra High Risk criteria).
4. Psychosocial support — maintenance of functional level, employment, social connections.
5. Cannabis cessation — crucial for reducing risk of psychotic decompensation.
6. Stress management — stress can be a trigger for decompensation.
7. Family psychoeducation — Information on transition markers to schizophrenia; patient's social support system.

8.2 Psychotherapy Approaches

• CBT — for paranoid thinking, social anxiety, cognitive impairments; reality testing and alternative explanations.
• Social skills training — reduction of social isolation and bizarre behaviors.
• Mentalization-based and supportive approaches — Enhancement of interpersonal functional level.
• Schema Therapy — For personality-based enduring models.

8.3 Pharmacotherapy — Specific Use

• Subclinical psychotic symptoms (referential ideas, odd experiences) when exacerbated — low-dose atypical antipsychotic intermittently.
• Comorbid depression — SSRI (sertraline, escitalopram).
• Social anxiety — SSRI, short-term benzodiazepine (for specific situations).
• Stress-induced decompensation — hospitalisation or short-term intensive intervention.

8.4 Source-Specific Clarifications

• Evidence base is limited — Extensive RCTs on specific treatment for schizotypal disorder are scarce; main approach extrapolated from interventions for schizophrenia and personality disorders.
• Studies by Koenigsberg H.W. et al. — Low-dose antipsychotic research in schizotypal disorder (moderate effect).
• NICE — No separate indication; CG178 and CG78 principles.

Treatment methods

1. Schizotypal Personality Questionnaire (SPQ — Schizotypal Personality Questionnaire) — Raine (Raine A.) — 74-item self-assessment scale; 9 subscales corresponding to DSM criteria for schizotypal personality disorder. Widely used in clinical and population studies.
2. Comprehensive Assessment of At-Risk Mental States (CAARMS) — Transition risk assessment to schizophrenia — subclinical level of positive symptoms, cognitive changes, behavioral impairments, functional level. Yung A.R. et al. Aust N Z J Psychiatry 2005.
3. Structured Interview for Prodromal Syndromes (SIPS) — Miller (Miller T.J.), McGlashan (McGlashan T.H.) — Similar to CAARMS; widely used in the USA.
4. Early Intervention Services (EIP) — For UHR patients — multidisciplinary intervention; antipsychotics usually not recommended prophylactically (side effect burden), psychosocial intervention superior.
5. Personality disorders adapted CBT — For schizotypal personality — working on cognitive impairments, social fears, paranoid thinking.
6. Social Skills Training — Structured group or individual sessions — development of social interaction skills.

9. Prognosis

Good prognostic factors

• Mild symptom intensity.
• Management of comorbidity (depression, anxiety, substance).
• Social support and sustained relationships.
• Psychotherapy participation.
• Cannabis cessation.

Poor prognostic factors

• Schizophrenia in family history.
• Cannabis or other psychoactive substance use.
• Severe cognitive deficits.
• Social isolation and functional impairment.
• Meeting UHR criteria.

Follow-up targets

• Periodic assessment of transition markers to schizophrenia (CAARMS / SIPS).
• Comorbidity screening (depression, anxiety, substance).
• Functional level — employment, social relationships.
• Management of stress and psychotic decompensation triggers.
• Monitoring side effects in patients taking antipsychotics.

10. Myths and misconceptions

10.1 Etiology and conceptual myths

Myth 1: “Schizotypal personality is just an ‘eccentric’ or ‘creative’ person, requiring no clinical diagnosis”

Why it is widespread: distribution of schizotypal traits (odd beliefs, eccentricity) as a continuous spectrum in the population — many in the general population carry mild forms of ‘schizotypy’ traits.

Clinical and biological rationale: clinical diagnosis functional impairment requires — social isolation, occupational impairment, distress. Simple creativity or eccentricity alone not diagnostic basis. But when criteria are met, schizotypal disorder is a real clinical condition benefiting from intervention.

Real clinical step: diagnosis should be based on criteria (5/9 symptoms + functional impairment).

Myth 2: “Schizotypal disorder inevitably converts to schizophrenia”

Evidence: Schultze-Lutter F. et al. Schizophr Res 2014 — transition from schizotypal disorder to schizophrenia ~10–25%; majority remain stable or show remission. Family history, cannabis use, severity of cognitive deficit increase transition risk.

Real clinical step: Provide family with realistic prognosis; UHR criteria are monitored; prophylactic antipsychotic usually not recommended.

Myth 3: “Schizotypal disorder arises from childhood trauma or poor upbringing”

Evidence: Genetic component is significant — Kety Danish adoptive studies; Cross-Disorder Group 2013. Childhood trauma is indicated as a risk factor, but not the main etiology; biological and psychosocial interaction.

10.2 Misguided treatment approaches

Myth 4: “Schizotypal patients must definitely take continuous antipsychotics”

Evidence: continuous antipsychotic not recommended for schizotypal disorder (limited evidence base + side effect burden). Low-dose antipsychotic intermittent can be used as symptom-specific intervention; for continuous assignment — individual assessment.

Myth 5: “Validating the schizotypal patient's ‘magical thinking’ is treatment”

Clinical logic: explicitly confirming delusion-like beliefs reinforces them; conversely, explicitly denying them also disrupts the therapeutic alliance. Reality testing and alternative explanations Evidence-based approach in CBT — the patient and therapist explore factual evidence for the belief or alternative explanations.

Myth 6: “Social isolation is a healthy strategy; the schizotypal patient should be left alone”

Evidence: Social isolation increases long-term functional level and risk of mood disorders. Gradual strengthening of social connections is recommended with social skills training and supportive therapy.

10.3 Ineffective methods or those delaying primary intervention

Myth 7: Alternative clinics based on magical thinking and “sixth sense” cure schizotypal disorder

Evidence: “Esoteric interventions” (crystal therapy, chakra work, astrology consultations) — may support bizarre beliefs of schizotypal patients and intensify disorder symptoms. No evidence of effect; delays primary psychotherapeutic or pharmacotherapeutic intervention.

Myth 8: Cannabis “preserves creativity and unusual experiences” — safe for schizotypal patients

Evidence: Cannabis increases psychosis risk by 2–3 times (Marconi 2016); conversion risk to schizophrenia is higher in schizotypal patients. Abstinence from cannabis is a critical clinical recommendation.

Myth 9: “Homeopathy, acupuncture, esoteric interventions cure schizotypal disorder”

Evidence: systematic reviews — the effect of these interventions for schizotypal disorder has not been proven.

Myth 10: “Schizotypal patient does not respond to psychotherapy, so simple observation is sufficient”

Evidence: CBT, social skills training, and supportive psychotherapy can help these patients; a ‘watchful waiting’ approach increases functional impairment.

11. Sources

1. WHO. ICD-11 for Mortality and Morbidity Statistics. 6A22 Schizotypal disorder. 2024.
2. American Psychiatric Association. DSM-5-TR. Washington DC: APA Publishing; 2022.
3. Pulay A.J., Stinson F.S., Dawson D.A. et al. Prevalence, correlates, disability, and comorbidity of DSM-IV schizotypal personality disorder: results from the wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. Prim Care Companion J Clin Psychiatry 2009;11(2):53–67.
4. Schultze-Lutter F., Klosterkötter J., Ruhrmann S. Improving the clinical prediction of psychosis by combining ultra-high risk criteria and cognitive basic symptoms. Schizophr Res 2014;154(1–3):100–106.
5. Hazlett E.A., Goldstein K.E., Kolaitis J.C. A review of structural MRI and diffusion tensor imaging in schizotypal personality disorder. Curr Psychiatry Rep 2012;14(1):70–78.
6. Raine A. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull 1991;17(4):555–564.
7. Yung A.R., Yuen H.P., McGorry P.D. et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry 2005;39(11–12):964–971.
8. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013;381(9875):1371–1379.
9. Marconi A., Di Forti M., Lewis C.M., Murray R.M., Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull 2016;42(5):1262–1269.
10. NICE Clinical Guideline 178. Psychosis and schizophrenia in adults: prevention and management. 2014, 2019 update.
11. Kety S.S., Rosenthal D., Wender P.H. et al. The types and prevalence of mental illness in the biological and adoptive families of adopted schizophrenics. J Psychiatr Res 1968;6(Suppl 1):345–362.
12. Miller T.J., McGlashan T.H., Rosen J.L. et al. Prodromal assessment with the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms. Schizophr Bull 2003;29(4):703–715.
13. Koenigsberg H.W., Reynolds D., Goodman M. et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 2003;64(6):628–634.